Incyte, Genesis Molecular AI expand molecular AI collaboration to accelerate drug discovery

Incyte, a global biopharmaceutical company, and Genesis Molecular AI, a leader in molecular AI, announced an expanded collaboration to deploy AI-driven drug discovery. The agreement will use Incyte’s proprietary experimental data to train Genesis’ next-generation GEMS AI platform, enhancing its ability to predict protein-ligand structures and optimize molecules. This builds on their initial partnership announced in February 2025, now broadening AI deployment across Incyte’s portfolio for challenging drug targets. The expanded deal includes five new collaboration targets selected by Incyte, with options for additional nominations. Incyte retains exclusive rights to develop and commercialize any resulting products. Genesis will receive $120 million upfront, including $80 million in cash and a $40 million equity purchase, along with ongoing research funding to support AI model training. Financial terms also include potential milestone payments of up to $232 million per program, with Genesis eligible for over $1 billion if all milestones are met across the five initial targets. Additional payments could reach several billion dollars depending on further targets and achievements. Genesis’ GEMS platform integrates AI and physics to generate and optimize drug molecules, accelerating the design-make-test cycles critical to drug development. Pablo J. Cagnoni, Incyte’s president and global head of R&D, stated the collaboration reflects the company’s commitment to advanced technologies for faster drug discovery. Evan Feinberg, Genesis CEO, highlighted the synergy between Incyte’s experimental data and Genesis’ AI capabilities, marking a significant step in AI-driven drug development. The partnership underscores the growing role of AI in pharmaceutical innovation, leveraging proprietary data to enhance molecular design and development efficiency.